In 2022, Janssen commissioned Biointelect to explore current approaches to reimbursement for new and promising medicines in Australia and internationally. The resulting report, Accelerating Access to Innovative Medicines analyses Australia’s current reimbursement pathways and compares them with international policies designed to accelerate access to medicines.
Research highlights that Australians are waiting longer for funded access to new medicines following regulatory approval than most OECD countries. This report has a particular focus on access to innovative medicines that receive market authorisation based on early or limited clinical trial data.
